2023
Raluca Pais, Bertrand Cariou, Mazen Noureddin, Sven Francque, Jörn M. Schattenberg, Manal F. Abdelmalek, Gadi Lalazar 8, Sharat Varma, Julie Dietrich, Veronica Miller, Arun Sanyal, Vlad Ratziu, on behalf of the Liver Forum NAFLD-Associated Comorbidities Working Group
2022
Deborah Donnell, Kidist Zewdie, Natasha Ratna, Veronica Miller, John Michael Saunders, O Noel Gill, Valerie Delpech, Hamish Mohammed
Hannah Imlay, Paul Baum, Daniel C Brennan, Kimberly E Hanson, Michael R Hodges, Aimee C Hodowanec, Takashi E Komatsu, Per Ljungman, Veronica Miller, Yoichiro Natori, Volker Nickeleit, Jules O’Rear, Andreas Pikis, Parmjeet S Randhawa, Deirdre Sawinski, Harsharan K Singh, Gabriel Westman, Ajit P Limaye BK Disease Definitions Working Group of the Transplantation Associated Virus Infection Forum With the Forum for Collaborative Research
Kelley M Kidwell, Satrajit Roychoudhury, Barbara Wendelberger, John Scott, Tara Moroz, Shaoming Yin, Madhurima Majumder, John Zhong, Raymond A Huml, Veronica Miller
Adam J. Gehring, Patricia Mendez, Kirsten Richter, Hildegund Ertl, Eric F. Donaldson, Poonam Mishra, Mala Maini, Andre Boonstra, Georg Lauer, An de Creus, Kathleen Whitaker, Sara Ferrando Martinez, Jessica Weber, Emily Gainor, Veronica Miller
JosephKin-On Laua, Nicholas Murdock, Jeffrey Murray, Jessica Justman, Neil Parkin, Veronica Miller
Fabien Zoulim, Adam Zlotnick, Stephanie Buchholz, Eric Donaldson, John Fry, Anuj Gaggar, Jianming Hu, Michael Kann, Oliver Lenz, Kai Lin, Nagraj Mani, Michael Nassal, William Delaney, Su Wang, Gabriel Westman, Veronica Miller & Harry L. A. Janssen
Neil Parkin, Fei Gao, Eduard Grebe, Amy Cutrell, Moupali Das, Deborah Donnell, Ann Duerr, David V Glidden, James P Hughes, Jeffrey Murray, Michael N Robertson, Joerg Zinserling, Joseph Lau, Veronica Miller; Forum for Collaborative Research Recency Assay Working Group
2021
The Use of External Controls in FDA Regulatory Decision Making
Mahta Jahanshahi, Keith Gregg, Gillian Davis, Adora Ndu, Veronica Miller, Jerry Vockley, Cecile Ollivier, Tanja Franolic, Sharon Sakai
Commentary title: COVID-19 research, Africa, and global health
Tinkhani Mbichila, Grace Kumwenda, Ntando Yola, Quarraisha Abdool Karim, Tamar Tchelidze, Joseph Lau, Stephanie Buchholz, Regine Lehnert, Jean-Michel Molina, Kenneth Mayer, Veronica Miller
2020
Oliver Glass, Claudia Filozof, Mazen Noureddin, Mark Berner-Hansen, Elmer Schabel, Stephanie O. Omokaro, Jörn M. Schattenberg, Katherine Barradas, Veronica Miller, Sven Francque, Manal F. Abdelmalek, on behalf of the Liver Forum Standard of Care Working Group
Mazen Noureddin, Jean L. Chan, Katherine Barradas, Lara Dimick-Santos, Elmer Schabel, Stephanie O. Omokaro, Frank A. Anania, Robert P. Myers, Veronica Miller, Arun J. Sanyal, Naga Chalasani, on behalf of the Liver Forum NASH Cirrhosis Working Group
2019
Liver safety assessment in clinical trials of new agents for chronic hepatitis B
Robert J. Fontana, Mark I. Avigan, Harry L. A. Janssen, Arie Regev, Poonam Mishra, Anuj Gaggar, Nathaniel Brown, Cynthia Wat, Patricia Mendez, Ryan T. Anderson, Bruce Given, Veronica Miller, Maria Beumont
Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease
Miriam B. Vos, Lara Dimick-Santos, Ruby Mehta, Stephanie O. Omokaro, Johannes Taminiau, Elmer Schabel, David E. Kleiner, Peter Szitanyi, Piotr Socha, Jeffrey B. Schwimmer, Stephanie Noviello, Debra G. Silberg, Richard Torstenson, Veronica Miller, Joel E. Lavine, on behalf of the Liver Forum Pediatric Working Group
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
Amanda Cheung, Brent A. Neuschwander-Tetri, David E. Kleiner, Elmer Schabel, Mary Rinella, Stephen Harrison, Vlad Ratziu, Arun J. Sanyal, Rohit Loomba, Sophie Jeannin Megnien, Richard Torstenson, Veronica Miller, on behalf of the Liver Forum Case Definitions Working Group
Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic Hepatitis B Virus
Ryan Taylor Anderson, Seng Gee Lim, Poonam Mishra, Filip Josephson, Eric Donaldson, Bruce Given, Veronica Miller
2018
Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials
Roy F. Chemaly, Sunwen Chou, Hermann Einsele, Paul Griffiths, Robin Avery, Raymund R. Razonable, Kathleen M. Mullane, Camille Kotton, Jens Lundgren, Takashi E. Komatsu, Peter Lischka, Filip Josephson, Cameron M. Douglas, Obi Umeh, Veronica Miller, Per Ljungman, the Resistant Definitions Working Group of the Cytomegalovirus Drug Development Forum
Case definitions for inclusion and analysis of endpoints in clinical trials for NASH through the lens of regulatory science
M. Shadab Siddiqui, Stephen A. Harrison, Manal F. Abdelmalek, Quentin M. Anstee, Pierre Bedossa, Laurent Castera, Lara Dimick-Santos, Scott Friedman, Katherine Greene, David Kleiner, Sophie Megnien, Brent A. Neuschwander-Tetri, Vlad Ratziu, Elmer Schabel,Veronica Miller, Arun J. Sanyal, On behalf of the Liver Forum Case Definitions Working Group
2017
Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile
Elena Ivanova Reipold, Philippa Easterbrook, Alessandra Trianni, Nivedha Panneer, Douglas Krakower, Stefano Ongarello, Teri Roberts, Veronica Miller and Claudia Denkinger
The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing
Joseph D. Tucker, Katherine Meyers, John Best, Karyn Kaplan, Razia Pendse, Kevin A. Fenton, Isabelle Andrieux-Meyer, Carmen Figueroa, Pedro Goicochea, Charles Gore, Azumi Ishizaki, Giten Khwairakpam, Veronica Miller, Antons Mozalevskis, Michael Ninburg, Ponsiano Ocama, Rosanna Peeling, Nick Walsh, Massimo G. Colombo and Philippa Easterbrook
Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum
Yuval A. Patel, Joanne C. Imperial, Andrew J. Muir, Quentin M. Anstee, David DeBrota, Lara Dimick-Santos, Claudia Filozof, Ruby Mehta, Arun J. Sanyal, Elmer Schabel, Brent A. Neuschwander-Tetri, Veronica Miller, on behalf of the Liver Forum’s Data Standardization Working Group.
Can Viral Load be used as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-anaylsis
Yoichiro Natori, Ali Alghamdi, Mahmood Tazari, Veronica Miller, Shahid Husain, Takashi Komatsu, Paul Griffiths, Per Ljungman, Ani Orchanian-Cheff, Deepali Kumar, Atual Humar on behalf of the CMV Consensus Forum
Liu J, Goicochea P, Block T, Brosgart C, Donaldson EF, Lenz O, Lim SG, Mishra P, Peters MG, Miller, V. Journal of Virus Eradication [Internet]. 2017 Jan [cited 2017 Jan 19]; (issn 2055-66-59 - online).
2016
Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials
Per Ljungman Michael Boeckh Hans H. Hirsch Filip Josephson Jens Lundgren Garrett Nichols Andreas Pikis Raymund R. Razonable Veronica Miller Paul D. Griffiths for the Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum
Human cytomegalovirus and transplantation: drug development and regulatory issues
McIntosh M, Hauschild B, and Miller V. Journal of Virus Eradication 2016 July, 2: 143-148
2015
Hepatitis C Virus Drug Resistance-Associated Substitutions: State of the Art Summary
Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Hongmei M, Parkin N, Pilot-Matias T, Miller V. Hepatology 2015 November, 62(5), 1623-1632.
Alessandra Trianni, Nivedha Paneer, and Claudia Denkinger with input from other stakeholders on behalf of meeting participants. 22 April 2015, Vienna, Austria
2014
HIV and HCV Infection in the United States: Whom and How to Test
Panneer N, Lontok E, Branson BM, Teo CG, Dan C, Parker M, Stekler JD, DeMaria A Jr, Miller V. Clin Infect Dis. 2014 May 27. pii: ciu396
Accelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group
Hutchison C, Kwong A, Ray S, Struble K, Swan T, Miller V. Accelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group. Clin Pharmacol Ther. 2014. Jun 25: 1532-6535
2013
The Untold Story of How High-Quality and Low-Cost Drugs Were Incorporated Into PEPFAR.
Quinones-Rivera, A. Annals Of The Forum For Collaborative HIV Research, 15(1). (2013).
Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype-1 Infection Response-Guided Therapy
Lontok E, Mani N, Harrington PR, Miller V. Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype-1 Infection Response-Guided Therapy. Clin Infect Dis. 2013 Jan 29. [Epub ahead of print]
2012
Recommendations for Standardized Nomenclature and Definitions of Viral Response in Trials of Hepatitis C Virus Investigational Agents
Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V; Definitions/Nomenclature Working Group* of the HCV DrAG (HCV Drug Development Advisory Group), under the auspices of the Forum for Collaborative HIV Research. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology. 2012 Dec;56(6):2398-403.
Clinically Relevant HCV Drug Resistance Mutations Figure and Tables (Updated)
HCV Phenotype Working Group, HCV Drug Development Advisory Group. Ann Forum Collab HIV Res. Volume 14 (2): 2012; 1-10.
Novel Clinical Trial Designs for the Development of New Antiretroviral Agents
Mani N, Murray J, Gulick RM, Josephson F, Miller V, Miele P, Strobos J, Struble KA. Novel clinical trial designs for the development of new antiretroviral agents. AIDS. 26(8):899-907, May 15, 2012.
Adverse Outcome Analyses of Observational Data: Assessing Cardiovascular Risk in HIV Disease
Triant V, Josephson F, Rochester CG, Althoff KN, Marcus K, Munk R, Cooper C, D'Agostino RB, Costagliola D, Sabin CA, Williams PL, Hughes S, Post WS, Chandra-Strobos N, Guaraldi G, Young SS, Obenchain R, Bedimo R, Miller V, Strobos J. Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease. Clin Infect Dis. 2012 Feb 1;54(3):408-13
2011
Safety Considerations in the Prevention of Transmission of HIV by Pre-Exposure Prophylaxis (or "PrEP")
Jur Strobos, Benjamin C Hauschild, Veronica Miller
Ann Forum Collab HIV Res: Vol 13, No 5. Nov. 28, 201.
Municipal Scale-up of HIV Testing in the United States: Current Status, Challenges and Opportunities from a Multi-Stakeholder Perspective
Benjamin C Hauschild, Veronica Miller, Jur Strobos
Ann Forum Collab HIV Res: Vol 13, No 4
Nov. 7, 2011
Recommendations from a Research Consultation to Inform the Next Generation of HIV Prevention Messaging for Men Who Have Sex with Men (MSM)
Jennifer Uhrig, Megan A Lewis, George Ayala,, Jo Ellen Stryker
Ann Forum Collab HIV Res
Oct. 3, 2011
Global Pharmacovigilance for Antiretroviral Drugs: Overcoming Contrasting Priorities
Bakare N, Edwards IR, Stergachis A, Pal S, Holmes CB, Lindquist M, et al. Global pharmacovigilance for antiretroviral drugs: overcoming contrasting properties. PLoS Med 2011 Jul;8(7):e1001054.Epub 2011 Jul 5.
Recognizing Leadership, Courage and Hands-On Engagement: Relearning Lessons 30 Years Later
Veronica Miller
Ann Forum Collab HIV Res
Mar. 29, 2011
Presentation of the C. Everett Koop HIV/AIDS Health Leadership Award to VADM C. Everett Koop, MD, SCD, 13th U.S. Surgeon General
Anthony S. Fauci
Ann Forum Collab HIV Res
Mar. 29, 2011
The Early Days of AIDS, As I Remember Them
C. Everett Koop
Ann Forum Collab HIV Res
Mar. 29, 2011
Sequence and Phenotypic Analysis for Resistance Monitoring in Hepatitis C Virus Drug Development: Recommendations from the HCV DRAG
Ann D. Kwong, Isabel Najera, Jill Bechtel, Steven Bowden, Joseph Fitzgibbon, Patrick Harrington, Dale Kempf, Tara L. Kieffer, Diana Koletzki, George Kukolj, Sharlene Lim, Tami Pilot-Matias, Kai Lin, Nina Mani, Hongmei Mo, Jules O'Rear, Michael Otto, Neil Parkin, Jean-Michel Pawlotsky, Christos Petropoulos, Gaston Picchio, Robert Ralston, Jacqueline D. Reeves, Robert T. Schooley, Scott Seiwert, David Standring, Lieven Stuyver, James Sullivan, Veronica Miller, Forum for Collaborative HIV Research, HCV Drug Development Advisory Group (HCV DrAG), Sequence Analysis Working Group (SAWG), Phenotype Analysis Working Group (PAWG). Sequence and phenotypic analysis for resistance monitoring in hepatitis c virus drug development: recommendations from the HCV DrAG. Gastroenterology. 2011 Mar 12;140(3):755-60
HIV Clinic Capacity and Medical Workforce Challenges: Results of a Survey of Ryan White Part C-funded Programs
Benjamin C. Hauschild, Andrea Weddle, Jenny K. Tegelvik, Christine Lubinski, Veronica Miller, Michael S. Saag
Ann Forum Collab HIV Res
Jan. 21, 2011
2010
2010 National Summit on HIV Diagnosis, Prevention and Access to Care. November 17, 2010
2009
The Forum for Collaborative HIV Research: A Model for an Integrated and Inclusive Approach to Clinical Research and Drug Development
Miller V. The forum for collaborative HIV research: a model for an integrated and inclusive approach to clinical research and drug development. Clin Pharmacol Ther. 2009 Sep 1;86(3):332-5. Sep. 1, 2009
Evaluation of Impact of Adult Male Circumcision Programs on HIV Incidence and Prevalence: Current Research, Gaps in Knowledge and Recommendations for Additional Research
Sarah Kim, Shrimant Mishra, Veronica Miller
Ann Forum Collab HIV Res
Apr. 23, 2009
Metrics and Evaluation Measures for Monitoring the Implementation of Routine HIV Testing in the U.S.
Benjamin Hauschild, Linda Onaga
Ann Forum Collab HIV Res
Apr. 23, 2009
2008
HIV Clinical Trial Design for Antiretroviral Development: Moving Forward
Chan-Tack KM, Struble KA, Morgensztejn N, Murray JS, Cheng B, Weller I, Miller V. HIV clinical trial design for antiretroviral development: moving forward. AIDS. 2008 Nov 30;22(18):2419-27.
Opt-Out Testing for Human Immunodeficiency Virus in the United States: Progress and Challenges
Bartlett JG, Branson BM, Fenton K, Hauschild BC, Miller V, Mayer KH. Opt-out testing for human immunodeficiency virus in the united states: progress and challenges. JAMA. 2008 Aug 27;300(8):945-951.
Initiatives for Developing and Comparing Genotype Interpretation Systems Step 1: External Validation of Existing Rules-Based Algorithm for Abacavir and ddI Evaluated on Virological Response
Assoumou L, Brun-V zinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, DeGruttola V, Miller V, Costagliola D. Initiatives for developing and comparing genotype interpretation systems step 1: external validation of existing rules-based algorithm for abacavir and ddI evaluated on virological response. Journal of Infectious Diseases. 2008 Aug 15;198(4):470-80.
Research Needs and Challenges in the Development of HIV Diagnostic and Treatment Monitoring Tests for Use in Resource-Limited Settings
Cheng B, Landay A, Miller V. Research needs and challenges in the development of HIV diagnostic and treatment monitoring tests for use in resource-limited settings. Curr Opin HIV AIDS;2008 Jul 1;3(4):495-503.
Meeting the Demand for Male Circumcision
Nyasha Bakare, Veronica Miller
Ann Forum Collab HIV Res
Jun. 17, 2008
ARV Drugs, Adverse Events, Case Definition, Grading, Laboratory Diagnosis and Treatment Monitoring
Veronica Miller
Ann Forum Collab HIV Res
Jun. 17, 2008
2007
HIV-TB Co-Infection: Meeting the Challenge
Nyasha Bakare, Veronica Miller
Ann Forum Collab HIV Res
Nov. 2, 2007
Rethinking the Approach to Expanded Access Programs
Eric Zechman, Ben Cheng, Veronica Miller
Ann Forum Collab HIV Res
Jun. 14, 2007
Collaborative Approaches to HIV Drug Development: Planning for Long-Term Monitoring of Safety in CCR5 Antagonist Development
John Fry, Johanna Bogulavsky Grossman, Veronica Miller
Ann Forum Collab HIV Res
Apr. 24, 2007
A New Era for HIV Prevention?
Chris Collins, Meagan Lyon, Veronica Miller
Ann Forum Collab HIV Res
Feb. 1, 2007
HIV and TB in the Context of Universal Access: What is Working and What is not? Meeting Report
The World Health Organization
hivforum.org
2007
2006
Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
Khalsa J, Vocci F, Altice F, Fiellin D, Miller V. Buprenorphine and HIV primary care: new opportunities for integrated treatment. Clin Infect Dis. 2006 Dec 15;43(4):169-72.
Pediatric HIV Diagnosis & Laboratory Monitoring
Veronica Miller
Ann Forum Collab HIV Res
Nov. 1, 2006
Racial Ethnic Minority Issues in HIV/AIDS
Craig Hunter, Veronica Miller
Ann Forum Collab HIV Res
Nov. 1, 2006
HIV-1 Viral Load Assays for Resource-Limited Settings
Fiscus SA, Cheng B, Crowe SM, Demeter L, Jennings C, et al. (2006) HIV-1 viral load assays for resource-limited settings. PLoS Med 3(10): e417. doi:10.1371/journal.pmed.0030417
International Public Health Dialogue on HIV Testing and Counselling Report
Public Health Agency of Canada
hivforum.org
Aug. 17, 2006
2005
Meeting Summary and Report: Developing and HIV Health Services Research Agenda
Jeffrey Levi, Veronica Miller
Ann Forum Collab HIV Res
Jun. 1, 2005
Antiretroviral Therapies for Treatment Experienced Patients: Current Status and Research Challenges
Struble KA, Murray JS, Cheng B, Gegeny T, Miller V, Gulick RM. Antiretroviral therapies for treatment experienced patients: current status and research challenges. AIDS. 2005 May 20;19(8):747-56.
Regulatory Considerations for the Treatment of Lipodystrophy
Sally Snyder, Ben Cheng, Veronica Miller
Ann Forum Collab HIV Res
May 1, 2005
Buprenorphine and Primary HIV Care
Jeanine Warden, Craig Hunter, Veronica Miller
Ann Forum Collab HIV Res
Mar. 2005
2004
Roundtable Report: Importance of Antiretroviral Drug Levels in Sanctuary Sites and Viral Reservoirs
Reddy YS, Kashuba A, Gerber J, Miller V. Roundtable report: importance of antiretroviral drug levels in sanctuary sites and viral reservoirs. AIDS Research and Human Retroviruses. 2004 Jul 5;19(3):167-76.
2003
Quality of HIV Care - Closing the Gap: A Report on the Findings from the Quality of HIV Care Project
Veronica Miller
Ann Forum Collab HIV Res
Dec. 4, 2003
Monitoring of long-term toxicities of HIV treatments: an international perspective
Greg Bisson, Robert Gross, Veronica Miller, Ian Weller, Alexander Walker, on behalf of the writing group
AIDS
Nov. 21, 2003
Protein Binding in Antiretroviral Therapies
Marta Boffito, David J. Back, Terrence F. Blaschke, Malcolm Rowland, Richard J. Bertz, John G. Gerber, and Veronica Miller on behalf of the roundtable participants
AIDS Research and Human Retroviruses
Nov. 9, 2003
QA/QC of CD4 and Viral Load Assays in the Resource-Limited Setting
Kevin Moody, Veronica Miller
Ann Forum Collab HIV Res
Oct. 30, 2003
Cardiovascular Risk in HIV Infection and Treatment
Mark Mascolini, Veronica Miller
Ann Forum Collab HIV Res
May 22, 2003
Forum for Collaborative HIV Research Summary of Executive Committee Retreat
Veronica Miller
Ann Forum Collab HIV Res
Mar. 19, 2003
STI Roundtable Discussion: Moving the Agenda Forward
Richard Jefferys, Veronica Miller
Ann Forum Collab HIV Res
Feb. 8, 2003
2002
What Defines HIV Lipodystrophy?
Mark Mascolini, Veronica Miller
Ann Forum Collab HIV Res
Sep. 23, 2002
Report of the Workshop: Sex and Gender Issues in HIV Disease
Veronica Miller
Ann Forum Collab HIV Res
Sep. 4, 2002
Cheaper HIV Drugs for Poor Nations Bring a New Challenge: Monitoring Treatment
Joan Stephenson
JAMA
Jul. 10, 2002
Transfer of HIV Diagnostic and Monitoring Technologies into Resource-Poor Settings
Le Transfert des Technologies pour le Diagnostic et le Monitoring de l'Infection VIH dans les Pays en Développement (French Version)
Mark Mascolini, Veronica Miller
Ann Forum Collab HIV Res
May 2002
Report from the 3rd International STI Workshop
Richard Jefferys, Veronica Miller
Ann Forum Collab HIV Res
Apr. 22, 2002
2001
Linkage and Integration of HIV Testing, Prevention, and Care
John Palen, Veronica Miller
Ann Forum Collab HIV Res
Oct. 2001
Linking HIV Testing, Prevention and Care
Helen Schietinger
Ann Forum Collab HIV Res
Sep. 21, 2001
Examining the Risk and Benefits of Directly Observed Therapy for Treatment of HIV Disease
Karen Eddelman
Ann Forum Collab HIV Res
Apr. 17, 2001
Immunologic Markers to Evaluate Immune-Based Therapies in HIV Disease Meeting Reporting
Mark Mascolini
Ann Forum Collab HIV Res
Feb. 6, 2001
Structured Treatment Interruptions Workshop Summary
Veronica Miller
Ann Forum Collab HIV Res
Jan. 31, 2001
Report of the DHHS Working Group on Dissemination of HIV Treatment Information
Veronica Miller
Ann Forum Collab HIV Res
2001
2000
Immune-Based Therapies: A Review of Clinical Endpoints Used in Trials of Selected Immunologic Agents
Karen Eddleman, Veronica Miller
Ann Forum Collab HIV Res
Dec. 1, 2000
Immune-Based Therapies and HIV Disease
Alan Landay, June Bray, Veronica Miller
Ann Forum Collab HIV Res
Dec. 7, 2000
Bone Metabolism and HIV Disease Meeting Report
Lawrence Raisz, Jane Aubin, Veronica Miller
Ann Forum Collab HIV Res
Aug. 29, 2000
Mitochondrial Toxicity and HIV Disease Meeting Report
Kees Brinkman, William Copeland, Veronica Miller
Ann Forum Collab HIV Res
Jun. 5, 2000
Meeting on Drug Interaction Research in HIV Disease
David Barr, Veronica Miller
Ann Forum Collab HIV Res
Apr. 1, 2000
1999
Adherence to HIV Therapy: Building a Bridge to Success
DHHS Health Resources and Services Administration (HRSA) and The Forum for Collaborative HIV Research in collaboration with NIH Office of AIDS Research
hivforum.org
Nov. 15, 1999
Adherence to Highly Active Antiretroviral Therapy (HAART) Among Individuals
David Barr, Robert D. Webster
hivforum.org
Nov. 15, 1999
The Potential of Patient Outcomes Research
Helen Schietinger
Ann Forum Collab HIV Res
Sep. 1, 1999
Simplifying Antiretroviral Treatment Regimens-A Summary of Current Research
Dave Gilden
hivforum.org
Jun. 1, 1999
Failure of Initial Antiretroviral Treatment Regimens
David Gilden
Ann Forum Collab HIV Res
Jan. 1999
The Challenges of Clinical Trial Design in Assessing the Effects of Anti-HIV Therapy in Heavily Pre-Treated Patients
David Barr
Ann Forum Collab HIV Res
1999
1998
David Barr Speech at 4th Conference on Drug Therapy in Glasgow, Scotland
David Barr
hivforum.org
Nov. 1, 1998
HIV Treatment Failure: A Review of Clinical Research
Mark Harrington, Julia Hidalgo
Ann Forum Collab HIV Res
Jun. 1, 1998
Metabolic Consequences of HIV Disease and Treatment
Robert Munk
Ann Forum Collab HIV Res
1998
Dissemination and Evaluation of Clinical Practice Guidelines for HIV
Tina Sogocio, David Barr
Ann Forum Collab HIV Res
1998
FCHR Project on Metabolic Abnormalities in HIV Disease and Treatment: The Need for an Interim Case Definition and a Study to Examine Prevalence
Susan Brobst
Ann Forum Collab HIV Res
1998
1997
Adherence to New HIV Therapies: A Research Conference
(Author)
hivforum.org
Nov. 21, 1997
1996
The Keystone National Policy Dialogue on Establishment of Studies to Optimize Medical Management of HIV Infection
Keystone National Policy Dialogue Keystone Center
Ann Forum Collab HIV Res
Aug. 2, 1996
